-
"first-in-class" anti-cancer candidate drug enters clinical Phase 1 trial for the treatment of patients with recurrent brain tumors
Time of Update: 2020-06-11
Today, Moleculin Biotech (announced the company's "first-in-class" anticancer candidate drug (entering the clinical phase 1 trial for the treatment of patients with recurrent brain tumors) ()
-
Amgevita, Humira's biosimilar developed by Amgevita, is available in Europe
Time of Update: 2020-06-11
recently, Aming announced that the company (the world's best-selling drug ( adalimumab, Adamu mono-resistant) has been launched on the European market throughout Europe on 16 October 2018, incl
-
An antifungal drug that could help destroy dormant cancer cells in intestinal tumors, study finds
Time of Update: 2020-06-11
scientists at the University of Cambridge's Cancer Research Centre have found that an antifungal drug used to treat nail infections (or help eliminate dormant cancer cells in intestinal tumours)
-
FDA accepts application for license to supplement biologics for Perilife's warranty combination of multiple myeloma therapy
Time of Update: 2020-06-11
multiple myeloma is blood cancer caused by plasma cell cancer in the bone marrow The normal function of pulp cells is to produce antibodies that help identify and eliminate germs But not only are ca
-
Agios Pharmaceuticals cancer drug TIBSOVO (ivosidenib) gets FDA approval
Time of Update: 2020-06-11
recently, cancer bio Pharmaceutical ( Pharmaceuticals) announced that its anticancer drug (ivosidenib) was approved by the U.S FDA (for use in an adult with a testing (Abbott RealTimeIDH1 a
-
FDA approves Mercay's heavy immunotherapy Keytruda to be marketed for treatment of large B-cell lymphoma
Time of Update: 2020-06-11
PMBCL is an invasive diffuse large B-cell lymphoma that accounts for about 2 to 4 percent of all non-Hodgkin lymphomas, a disease that mainly affects young people and is about 1.7-2 times more likel
-
Patisiran significantly improves overall health of patients compared to placebo, study finds
Time of Update: 2020-06-11
today, the of the Peripheral Nerve Association (Peripheral Nerve Society) at the annual meeting of the company's RNAi therapeutic patisiran therapeutic hereditary ATTR (hATTR) amylodosis clinical
-
FDA approves Phase II clinical study application for New Small Molecule JAK1 Inhibitor SHR0302
Time of Update: 2020-06-11
ulcerative colitis is an autoimmune disease, inflammatory lesions are limited to the mucous membrane of the large intestine and the lower mucous membrane, mainly ulcer erosion The lesions may affect
-
Moshad east Zerbaxa treatment HABP or VABP critical Phase III clinical study reaches major endpoint
Time of Update: 2020-06-11
recently, the U.S Pharmaceutical (Merck and Co) announced that the critical Phase III clinical study (NCT0207757) for the treatment of the antibiotic Zerbaxa (ceftolozane/tazobactam) in hospitals
-
FDA approves launch of Pfizer's third-generation ALK tyrosine kinase inhibitor Lorbrena
Time of Update: 2020-06-11
lung cancer is one of the leading causes of cancer death in the world Lung cancer kills more people each year than colon, breast and prostate cancer combined Recently, Pfizer Inc (announced that
-
FDA accepts application for license to supplement biologics for its heavy immunotherapy Keytruda
Time of Update: 2020-06-11
recently, MSD announced that it FDA (receiving a supplementary biologic license (sBLA) for its heavy immunotherapy Keytruda (pembrolizumab) to treat adults and children with recurrent pre-localize
-
AstraZeneca and Mercado's PARP inhibitor Lipdro has been approved for listing by the National Drug Administration
Time of Update: 2020-06-11
today, AstraZeneca and Mersa East China jointly announced that its PARP inhibitor, Leopacho (Olapari, overseas, Lynparza), has been approved by the National Medicines (Supervisory Authority) for t
-
The treatment and survival of new drugs have improved significantly in the treatment and survival of set cell lymphoma
Time of Update: 2020-06-11
set of cell lymphoma (mantle cell lymphoma, MCL) has changed dramatically in recent years, with clinical results showing a significant increase in patient survival recently, scientists from the Uni
-
Merthyr's heavy anti-PD-1 cancer immunotherapy Keytruda Phase 3 clinical trial reaches major endpoint
Time of Update: 2020-06-11
Today, The of The of Mercadon (announced that the company's heavy-duty anti-PD-1 cancer immunotherapy Keytruda, as a second-line therapy, reached the primary end of the phase 3 clinical trial in
-
Sandoz's infliximab biosimilar zeslym approved by the European Commission
Time of Update: 2020-06-11
recently, Sandoz announced that its company, , which produces the infliximab biosimilar drug Zessly, has been granted access to the European market through european commission approval about Infli
-
Tianyuan Bio-Innovation Drug TJ107 (HyLeukin ®) approved by China's State Drug Administration
Time of Update: 2020-06-11
recently, Tianyuan Biotech (Shanghai) Limited Company (announced that its new new drug for cancer immunotherapy, (HyLeukin ®) has been approved by the China National Medicines (China Natio Me
-
Phase 2b study of diluted polyvicanone iodine in Veloce's new DMSO solvent system yielded positive results
Time of Update: 2020-06-11
yesterday (October 8), Veloce BioPharma, LLC ("Veloce")," announced positive results from its Phase 2 b study on dilution of polyvione iodine in the new DMSO solvent system, which is used for local
-
FDA approves Novartis' new oral targeted cancer drug Kisqali for treatment of patients with advanced or metastatic breast cancer
Time of Update: 2020-06-11
recently, Swiss Pharmaceutical scoundrel Novartis announced that the U.S Food and Drug ( FDA () has approved the new oral targeting anti-cancer drug Kisqali (ribociclib) for the treatment of pat
-
FDA approves for launch of Therapeutics MD's BIJUVA ™ capsule (1 mg/100 mg)
Time of Update: 2020-06-11
as the ovaries stop producing hormones and circulating estrogen levels drop, they often develop symptoms of tube aureus (VMS, also known as hot/tidal), as well as sleep and mood disorders and urinar
-
BMS Announces Phase II ELOQUENT-3 Study Reaches Major End
Time of Update: 2020-06-11
recently, BMS announced at the EHA 2018 annual meeting that the second phase of the ELOQUENT-3 study reached its main endpoint, with empliciti (elotuzumab) combining pomaduamine and low-dose dexamet
